Biotech Growth has reported results for the 12 months ended 31 March 2023 and they aren’t good. The NAV total return for the year was -11.0%, a whopping 16.4 percentage points behind the +5.4% return on the NASDAQ Biotechnology Index. The return to shareholders was -12.8%. The chairman’s statement attributes the underperformance to investors’ preference […]
As well as the formal proceedings, there will be an opportunity for shareholders to meet the Board and the Portfolio Manager, and to receive an update on the Company’s strategy and its key investments. Last year the heatwave in July may have prevented some shareholders from attending the AGM, so I very much look forward […]
The Biotech Growth Trust (BIOG) has announced its interim results for the six months ended 30 September 2022. Its chairman, Roger Yates, says that after a very difficult year to 31 March 2022, during which the trust’s NAV fell substantially and underperformed its benchmark (the NASDAQ Biotechnology Index), the first six months of the current year have seen […]
Investment trust insider on Biotech Growth – James Carthew: BIOG believes the biotech tide has turned Following my recent look at the biotech sector, I thought I would return to Biotech Growth (BIOG) which held its annual general meeting last week when investors got to hear from fund manager Geoff Hsu of Orbimed. The sector […]
BIOG’s AGM will be held at the Apothecaries’ Hall, 10 Blackfriars Lane, London EC4V 6ER on Tuesday, 19 July 2022 at 12 noon. As well as the formal proceedings, there will be an opportunity for shareholders to meet the Board and to receive an update from the Portfolio Manager on the Company’s strategy and its […]
Biotech Growth hit by broader market turmoil as it enters 25th year – Biotech Growth (BIOG) has published its final results for the year to 31 March 2022. During the period under review, the company’s NAV per share total return was down 33.8% while its share price total return was down 37%. This compares with […]
Dramatic year for Biotech Growth – as its chairman says “as a result of the COVID-19 pandemic the year to 31 March 2020 proved to be one of the most dramatic in the history of the company since its inception in 1997.” For the year to 31 March 2020, the net asset value per share […]
Biotech Growth tops bio-trust league with 47% NAV rise – Orbimed-managed Biotech Growth Trust (BIOG) recorded the rise 47% rise in NAV in 2019, representing the best performance of the 14 specialist biotech/pharma closed end investment vehicles monitored by Marten & Co. Biotech Growth’s rise in NAV was more than double that of the benchmark […]
Biotech Growth extends run of poor performance – On Friday, Biotech Growth Trust published results for the year ended 31 March 2019. Its net asset value per share rose by 5.3% and the share price by 4.6%, reflecting a slight widening in the discount. The benchmark (Nasdaq Biotechnology Index) returned 13.0%. Biotech Growth Trust has now […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated